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INTRODUCTION 
 
Chronic kidney disease results when a disease process affects the 
structural or functional integrity of the kidneys. Chronic kidney failure is 
the result of chronic kidney disease. 
 
Chronic renal disease features various abnormalities of lipid  
metabolism, which results in an exceedingly atherogenic  profile. 
Although most striking  lipid  abnormalities are seen in nephrotic  
syndrome, hyperlipidemia characterizes renal disease of every cause. 
 
Lipid  abnormalities in Chronic renal failure are very important, 
because  atherosclerotic heart disease is the foremost cause of  morbidity 
and mortality in patients with end stage renal disease   
 
Cardiovascular diseases are the leading causes of  death in end 
stage renal disease largely as the result of progressively increasing age of 
ESRD patients and the broad constellation of uremia associated features . 
 
 When the kidney function has deteriorated and is no longer 
adequate to sustain life, renal replacement therapy (RRT), dialysis or 
transplantation becomes necessary to maintain life. Hence, it is important 
to prevent the development of chronic renal insufficiency and subsequent 
progression to ESRD. Unfortunately  kidney disease in its early stages in 
generally asymptomatic. Early identification of patients at risk for chronic 
kidney disease is essential. Major risk factors for the development and 
progression of chronic kidney disease include diabetes, high blood 
pressure, protein barrier, family history of kidney disease and increasing 
age. The progression of kidney disease to end stage can be slowed by 
glycemic control (in diabetes), blood pressure control for the patients 
with high blood pressure and use of angiotension converting enzyme 
(ACE) inhibitors.  
 
 Cardiovascular disease is the major cause of death among patients 
with chronic renal failure and ESRD (end stage renal disease). In addition 
to impairing the microcirculation hypertension may contribute to the 
development of atherosclerotic coronary artery disease particularly in the 
presence of many lipid abnormalities observed in end stage renal disease. 
The patients have reduced HDL-cholesterol and increased plasma 
triglyceride concentrations and there is defect in the cholesterol transport. 
Other factors that may contribute to atherosclerotic coronary artery 
disease in end stage renal disease are reduced HDL-cholesterol synthesis 
and reduced activity of the reverse cholesterol pathway.   
 
 Also, a growing amount of clinical experience data suggests that 
lipids may be important in the development and progression of chronic 
renal disease. Potentially injurious lipid abnormalities are invariably 
present in these patients more likely to progress to end stage renal disease. 
 
 So, the analysis of lipoprotein subclass in chronic renal failure 
patients is very much essential to assess the clinical outcome. 
REVIEW OF LITERATURE 
 
 
LIPOPROTEIN METABOLISM 
 
 Lipoproteins are large, mostly spherical complexes that transport 
lipids (primarily triglycerides, cholesteryl esters), and fat-soluble 
vitamins through body fluids (plasma, intestinal fluid, and lymph) to and 
from tissues. They play an essential role in the absorption of dietary 
cholesterol, long chain fatty acids, and fat-soluble vitamins from the liver 
to peripheral tissues; and the transport of cholesterol from peripheral 
tissues to the liver.  
 
 Lipoproteins contain a core of hydrophobic lipids (triglycerides and 
cholesteryl esters) surrounded by hydrophilic lipids (phospholipids, 
unesterified cholesterol) and proteins that interact with body fluids. The 
plasma lipoproteins are divided into five major classes based on their 
relative densities: chylomicrons, very low-density lipoproteins (VLDL), 
intermediate-density lipoproteins (IDL), low-density lipoproteins (LDL), 
and high-density lipoproteins (HDL). 
 
 Each lipoprotein class comprises a family of particulars that vary 
slightly in density, size, and migration during electrophoresis, and protein 
composition. The density of a lipoprotein is determined by the amount of 
lipid and protein per particle. HDL is the smallest and most dense 
lipoprotein, whereas chylomicrons and VLDL are the largest and least 
dense lipoprotein particles. Most triglyceride is transported in 
chylomicrons or VLDL, and most cholesterol is carried as cholesteryl 
esters in LDL and HDL. 
 
 The apolipoproteins are required for the assembly and structure of 
lipoproteins. Apolipoproteins also serve to activate enzymes important in 
lipoprotein metabolism and to mediate the binding of lipoproteins to cell 
surface receptors. ApoA-I, which is synthesized in the liver and intestine, 
is found on virtually all HDL1 particles. ApoA-II is the second most 
abundant HDL apolipoprotein and is found on approximately two-thirds 
of all HDL particles. 
 
 ApoB is the major structural protein of chylomicrons, VLDL, IDL, 
and LDL. One molecule of ApoB, either ApoB-48 (chylomicrons) or 
apoB-100 (VLDL, IDL, or LDL), is present on each lipoprotein particle. 
The human liver makes only apoB-100, and the intestine makes apoB-48. 
ApoE is present in multiple copies on chylomicrons, VLDL, and IDL 
plays a critical role in the metabolism and clearance of triglyceride-rich 
particles. Three apolipoproteins of the C-series (apoC-I, -II and -III) also 
participate in the metabolism of triglyceride-rich lipoproteins.  
 
TRANSPORT OF DIETARY LIPIDS (EXOGENOUS PATHWAY) 
  
 Dietary triglycerides are hydrolyzed by pancreatic lipases within 
the intestinal lumen and are emulsified with bile acids to form micelles. 
Dietary cholesterol and retinol are esterified (by the addition of a fatty 
acid) in the enterocyte to form cholesteryl esters, respectively. 
 
 Longer-chain fatty acids (>12 carbons) are incorporated into 
triglycerides and packaged with apoB-48, cholesteryl esters, retinyl esters, 
phospholipids, and cholesterol to from chylomicrons. Nascent 
chylomicrons are secreted into the intestinal lymph and delivered directly 
to the systemic circulation, where they are extensively processed by 
peripheral tissues before reaching the liver. The particles encounter 
lipoprotein lipase (LPL), which is anchored to proteoglycans that 
decorate the capillary endothelial surfaces of adipose tissue, heart, and 
skeletal muscle. The triglycerides of chylomicrons are hydrolyzed by 
LPL, and free fatty acids are released; apoC-II, which is transferred to 
circulation chylomicrons, acts as a cofactor for LPL in this reaction. The 
released free fatty acids are taken up by adjacent myocytes or adipocytes 
and either oxidized or re esterified and stored as triglyceride. Some free 
fatty acids bind albumin and are transported to other tissues, especially 
the liver. 
 
 The chylomicrons particle progressively shrinks in size as the 
hydrophobic core is hydrolyzed and hydrophilic lipids (cholesterol and 
phospholipids) on the particle surface are transferred to HDL. The 
resultant smaller, more cholesterol ester-rich particles are referred to as 
chylomicrons remnants. The remnants particles are rapidly removed from 
the circulation by the liver in a process that requires apoE.1. 
 
TRANSPORT OF HEPATIC LIPIDS (ENDOGENOUS 
PATHWAY) 
 This one refers to the hepatic secretion and metabolism of VLDL 
to IDL and LDL. VLDL particles resemble chylomicrons in protein 
composition but contain apoB-100 rather than apoB-48 and have a higher 
ratio of cholesterol to triglyceride (~1 mg of cholesterol for every 5 mg of 
triglyceride). The triglycerides of VLDL are derived predominantly from 
the esterification of long chain fatty acids. 
 
 The packing of hepatic triglycerides with the other major 
components of the nascent VLDL particle (apoB-100, cholesteryl esters, 
phospholipids, and vitamin E) requires the action of the enzyme 
microsomal transfer protein (MTP). After secretion into the plasma, 
VLDL acquires multiple copies of apoE and apolipoproteins of the C 
series. The triglycerides of VLDL are hydrolyzed by LPL, especially in 
muscle and adipose tissues.1 
 
 As VLDL remnants undergo further hydrolysis, they continue to 
shrink in size and become IDL, which contain similar amounts of 
cholesterol and triglyceride. The liver removes approximately 40 to 60 % 
of VLDL remnants and IDL by LDL receptor-mediated endocytosis via 
binding to apoE. The reminder of IDL is remodeled by hepatic lipase 
(HL) to form LDL; during this process, most of the triglyceride in the 
particle is hydrolyzed and all apolipoproteins except apoB-100 are 
transferred to other lipoproteins. 
 
 The cholesterol in LDL amounts for ~70 % of the plasma 
cholesterol in most individuals. Approximately 70 % of circulating LDLs 
are cleared by LDL receptor-mediated endocytosis in the liver. 
Lipoprotein (a) [Lp(a)] is a lipoprotein similar to LDL in lipid and protein 
composition, but it contains an additional protein called apolipoprotein 
(a) [apo (a)]. Apo (a) is synthesized in the liver and is attached to apoB-
100 by a disulfide linkage. The mechanism by which Lp (a) is removed 
from the circulation is not known. 
 
HDL METABOLISM AND REVERSE CHOLESTEROL 
TRANSPORT 
 All nucleated cells synthesize cholesterol but only hepatocytes can 
efficiently metabolize and excrete cholesterol from the body. The 
predominant route of cholesterol elimination is by excretion into the bile, 
either directly or after conversion to bile acids. Cholesterol in peripheral 
cells is transported from the plasma membranes of peripheral cells to the 
liver by an HDL mediated process termed Reverse Cholesterol Transport1. 
 
 Nascent HDL particles are synthesized by the intestine and the 
liver. The newly formed discodial HDL particles contain apoA-I and 
phospholipids (mainly lecithin) but rapidly acquire unesterified 
cholesterol and additional phospholipids from peripheral tissues via 
transport by the membrane protein ATP-binding cassette protein A 
(ABCA). Once incorporated in the HDL particle, cholesterol is esterified 
by lecithin-cholesterol acyltransferase (LCAT), a plasma enzyme 
associated with HDL. As HDL acquires more cholesteryl ester it becomes 
spherical, and additional apolipoproteins and lipids are transferred to the 
particles from the surfaces of chylomicrons and VLDL during lipolysis. 
 
 HDL cholesterol is transported to hepatocytes by both an indirect 
and a direct pathway. HDL cholesteryl esters are transferred to apoB-
containing lipoproteins in exchange for triglyceride by the cholesteryl 
ester transfer protein (CETP). The cholesteryl esters are then removed 
from the circulation by LDL receptor-mediated endocytosis. HDL 
cholesterol can also be taken up directly by hepatocytes via the scavenger 
receptor class BI (SR-BI), a cell surface receptor that mediates the 
selective transfer to cells. 
 
 HDL particles undergo extensive remodeling within the plasma 
compartment as they transfer lipids and proteins to lipoproteins and cells. 
For example, after CETP-mediated lipid exchange, the triglyceride-
enriched HDL becomes a substrate for LPL, which hydrolyzed the 
triglycerides and phospholipids to generate smaller HDL particles.             
 
Transport of endogenous hepatic lipids via VLDL, IDL, and LDL. 
Note the relative and absolute changes in apoproteins, other than 
apoB100, as VLDL is converted to IDL and LDL. The sites of action of 
the two lipases, LPL and HTGL, are denoted. 
Transport of exogenously derived lipids from the intestine to 
peripheral tissues and liver via the chylomicrons system.HDL metabolism 
and the role of HDL in reverse cholesterol transport. Free cholesterol is 
accepted from peripheral tissues by HDL3 and, after esterification, may be 
transferred to apoB100 lipoproteins. 
 
Physical-Chemical Characteristics of the Major Lipoprotein Classes 
Lipid % Lipoprotein Density, g/dl Molecular 
Mass, kDa 
Diameter 
nm 
TG Chol PL 
Chylomicrons 0.95 400 x 103 75-1200 80-95 2-7 3-9 
VLDL 0.95-1.006 10-80x103 30-80 55-80 5-15 10-20 
IDL 1.006-1.019 5-10x103 25-35 20-50 20-40 15-25 
LDL 1.019-1.063 2.3x103 18-25 5-15 40-50 20-25 
HDL 1.063-1.210 1.7-3.6x102 5-12 5-10 15-25 20-30 
    
The remaining percent composition is made up of the apoproteins. 
Note: TG, triglyceride; Chol, the sum of free and esterified 
cholesterol; PL, phospholipids; VLDL, very low density lipoprotein; IDL, 
intermediate density lipoprotein; LDL, low density lipoprotein; HDL, 
high density lipoprotein. 
 
Pathophysiology of Dyslipidemia in CKD and Dialysis: 
 The spectrum of dyslipidemia in patients with CKD and dialysis 
patients is distinct from that of the general population. It involves all 
lipoprotein classes and shows considerable variations depending on the 
stage of CKD5. There seems to be a gradual shift to the uremic lipid 
profile as kidney function deteriorates, which is further modified by 
concurrent illnesses such as diabetes16 and nephrotic syndrome17. Apart 
from quantitative differences major qualitative changes in lipoproteins 
can be observed, such as oxidization and modification to sdLDL, which 
render the particles more atherogenic. 
 
Hypertriglyceridemia: 
 Plasma triglycerides start to increase in early stages of CKD and 
show the highest concentrations in nephrotic syndrome and in dialysis 
patients, especially those who are treated with peritoneal dialysis (PD). 
Plasma triglycerides are predominantly found in two types of lipoproteins 
in normal individuals. These are chylomicrons, which are assembled in 
the intestine for the transport of dietary fatty acids,18-20 and VLDL which 
are produced in the liver for the transport of endogenous fatty acids. The 
accumulation of triglycerides is the consequence of both a high 
production rate and a low fractional catabolic rate. An increased 
production of triglyceride rich lipoproteins is possibly a consequence of 
impaired carbohydrate tolerance and enhanced hepatic VLDL synthesis21. 
The reduced fractional catabolic rate is likely due to the decreased 
activity of two endothelium associated lipases, namely, LPL and hepatic 
triglyceride lipase, which have the primary physiologic function of 
cleaving triglycerides into FFA for energy production or storage. The 
cause of the decreased lipase activities in uremia is thought to be 
depletion of the enzyme pool induced by frequent hyalinization in 
hemodialysis (HD) patients22, an increase in the plasma apoC-III/apoC-II 
ratio, and the presence of other lipase inhibitors in plasma. ApoC-II is an 
activator of LPL, whereas apoC-III is an inhibitor of LPL. The increased 
apoC-III/apoC-II ratio is usually due to a disproportionate increase in 
plasma apoC-III23. The impaired lipase activities in uremic plasma may 
also be caused by a decrease in LPL synthesis as a result of secondary 
hyperparathyroidism or suppressed insulin level 24. 
 
 Incomplete catabolism result in the accumulation of remnant 
particles (chylomicrons remnants and IDL) that contribute to the 
heterogeneity of the plasma pool of triglyceride-rich lipoproteins with 
different sites of origin, sizes, compositions25, and degrees of 
atherogenicity.26 These remnants are rich in apoE, a ligand that is critical 
for the removal of the particles from the circulation by binding to LPR 
and perhaps other receptor on the vascular wall27. The arterial wall 
therefore is exposed to high plasma levels of remnant lipoproteins for 
prolonged durations, which may predispose to atherogenesis. 
 
High Density Lipoprotein: 
 Patients with CKD generally have reduced plasma HDL cholesterol 
concentrations compared with nonuremic individuals. Furthermore, the 
distribution of HDL subfractions are different. Because of the low apo-AI 
level and decreased LCAT activity8  the esterification of free cholesterol 
and hence the conversion of HDL3 to HDL2 are diminished in uremia. 
This decreased ability of the HDL particles to carry cholesterol leads to 
an impairment in the reverse cholesterol transport from peripheral cells to 
the liver, thereby burdening the vasculature with cholesterol and 
promoting atherosclerosis28-30. 
 
 Another important component of HDL is paraoxonase, an enzyme 
that inhibits the oxidation of LDL. Plasma paraoxonase activity is 
reduced in patients with CKD31, thereby predisposing the LDL and 
possibly also HDL particles to oxidation. Furthermore infection 
associated or uremia associated inflammation might convert HDL from 
an antioxidant into a pro-oxidant particle32,33. All of these may contribute 
to atherogenesis in CKD. 
Apolipoprotein A-IV: 
 ApoA-IV is a 46-kDa glycoprotein that is synthesized primarily in 
enterocytes of the small intestine. In vitro studies suggest that apoA-IV 
might protect against atherosclerosis by promoting several steps in the 
reverse cholesterol transport pathway, which removes cholesterol from 
peripheral cells and directs the cholesterol to liver and steroidogenic 
organs for metabolism34-36. Specifically apoA-IV activates LCAT37,38 and 
modulates the activation of LPL 39 as well as the protein-mediated 
transfer of cholesteryl esters from HDL to LDL40. Cross sectional studies 
have shown an inverse relationship between plasma apoA-IV levels and 
presence of coronary artery disease in the general population41,42 as well 
as in patients with CKD. 
 
 ApoA-IV has also been identified as a marker of primary CKD, 
and its plasma levels are already increased when glomerular filtration rate 
(GFR) is still normal. Furthermore, high plasma apoA-IV concentrations 
predicted, independent of baseline GFR, the progression of primary 
nondiabetic kidney disease, defined as doubling of serum creatinine or 
necessity of renal replacement therapy, during a prospective 7-yr follow-
up study43. These findings were unexpected, given the physiologic 
functions in reverse cholesterol transport and the antioxidative properties 
of apoA-IV. The high apoA-IV levels44 that were caused by the 
impairment of GFR are further modulated by nephrotic syndrome. 
Specifically, a tubular type of proteinuria cause a decrease in plasma 
apoA-IV levels. These observations suggest that the human kidney is 
involved in apoA-IV metabolism, a hypothesis that is further supported 
by the presence of apoA-IV in kidney tubular cells45. In dialysis patients, 
apoA-IV levels are twice as high as in the general population46-49. 
 
Low-Density Lipoprotein: 
 Elevated plasma LDL cholesterol concentration is common in 
nephritic syndrome but is not a typical feature of patients with advanced 
CKD, especially those who are on HD. There are, however, qualitative 
changes in LDL in patients with CKD and dialysis patients. The 
proportions of sdLDL and IDL, which are considered to be highly 
atherogenic, are increased sdLDL is a subtype, of LDL that has high 
propensity to penetrate the vessel wall, becomes oxidized, and triggers 
the atherosclerotic process. IDL is an intermediate metabolite of VLDL 
that is normally further degraded to LDL with the cleavage of 
triglycerides by lipases. Because of decreased hepatic triglyceride lipase 
activities in HD patients, the conversion of IDL to LDL is impaired and 
IDL accumulates 50 in plasma. IDL and sdLDL have high affinity for 
macrophages, which theoretically promote their entry into the vascular 
wall to participate in the formation of foam cells and atherosclerotic 
plaques51-54. The plasma levels of apoB, which is the major 
apolipoprotein of LDL an IDL, are strongly correlated with levels of 
these lipoproteins. 
 
 A vicious cycle has been suggested in uremia in which the 
decreased catabolism of IDL and LDL leads to their increased plasma 
residence time and further modification of the apoB contained in these 
lipoproteins by oxidation, carbamylation, and glycation. These 
modifications lead to the reduced recognition and binding of these 
lipoproteins to LDL receptors and LRP in the liver and hence further 
reduction in plasma clearance by this physiologic pathway. Using stable 
isotope techniques, it was shown recently that the plasma residence time 
of LDL and IDL is more than twice as long in HD patients as in 
nonuremic individuals. This reduced catabolism, however, is masked by 
the decreased production of LDL, resulting in near normal plasma levels 
of LDL55. In contrast to the decreased clearance by the liver, there is an 
increased clearance of these altered lipoproteins via the scavenger 
pathway. Modified LDL particles, such as ox-LDL and 
malonodialdehyde-modified LDL, are taken up by macrophages via 
binding to several cell surface scavenger receptors. The accumulation of 
cholesterol leads to the transformation of macrophages into foam cells in 
the vascular wall and contributes to atherogenesis51-54,56. 
 
 Kinetic parameters of apolipoprotein B (apoB) in LDL, apoB in 
IDL and apolipoprotein(a) [apo(a) in Lp(a). The concentration, 
production rate, and residence time in plasma are presented for control 
subjects (light green) and HD patients (dark green). Each bar represents 
mean + SEM. Data for LDL and IDL are derived from reference; data for 
Lp(a) are derived from reference. Despite differences in the production 
rate and residence time, there were no statistically significant differences 
in plasma concentration of the three lipoprotein particles between HD 
patients and nonuremic control subjects.  
 
Lipoprotein(a): 
 There is strong evidence that lipoprotein(a) [Lp(a) is a risk factor 
for CVD in the general population57,58. Lp(a) is an LDL-like lipoprotein 
that consists of apo(a) that is covalently bound to an LDL particle. Apo(a) 
shows a high homology with Plasminogen and competes with this protein 
for binding to Plasminogen receptors, fibrinogen, and fibrin59. Plasma 
Lp(a) concentrations are strongly genetically determined by the apo(a) 
gene, which contains a heritable number of kringle-IV (K-IV) repeats. 
The number of K-IV repeats is the basis for the apo(a) K-IV repeat 
polymorphism60. The molecular weight of apo(a) increases with the 
number of K-IV repeats ranging from 300 to >800 kDa, and is inversely 
related to the plasma Lp(a) concentration. Thus, individuals with high 
molecular weight or large apo(a) isoforms have on average low plasma 
Lp(a) concentrations, whereas those with low molecular weight or small 
isoforms usually exhibit high plasma Lp(a) concentrations. Depending on 
the population under investigation, this association explains between 30 
and 70% of the variability in plasma Lp(a) levels. 
 
 In kidney disease, plasma Lp(a) levels are also influenced by GFR. 
In patients with large apo(a) isoforms but not those with small apo(a) 
isoforms, plasma Lp(a) levels begin to increase in stage 1 CKD before 
GFR starts to decrease. This isoform specific increase in plasma Lp(a) 
levels was observed in several but not all studies in non-nephrotic 
patients with CKD and HD patients49,61-64. In contrast, in patients with 
nephrotic syndrome and PD patients65,66, increase in plasma Lp(a) levels 
occur in all apo9a) isoform groups, probably as a consequence of the 
pronounced protein loss and a subsequently increased production in the 
liver67. After successful kidney transplantation, a decrease in plasma 
Lp(a) can be regularly observed in HD patients with large apo(a) 
isoforms and in PD patients with all apo(a) isoform groups68,69. Thus, the 
elevation of Lp(a) in CKD is an acquired abnormality, mostly influenced 
by the degree of proteinuria and less by the cause of kidney disease49. 
 
 In vivo turnover studies using stable isotope techniques recently 
elucidated the mechanism for the increased plasma Lp(a) levels in HD 
patients. The production rates of apo(a) and apoB, the two 
apolipoproteins that are contained in Lp(a), were normal when compared 
with control subjects with similar plasma Lp(a) concentrations. The 
fractional catabolic rate of these apolipoproteins, however, was 
significantly reduced compared with control subjects. This resulted in a 
much longer residence time in plasma of almost 9 days for apo(a), 
compared with only 4.4 days in control subjects. This decreased clearance 
is likely the result of loss in kidney function in HD patients71. 
 
 Malnutrition and inflammation have also been associated with high 
plasma Lp(a) levels in HD patients63,64,72,73. The elevation of plasma Lp(a), 
however, can even be observed in patients with normal plasma C-reactive 
protein and/or normal plasma amyloid A levels64. It therefore seems that 
inflammation only modifies Lp(a) concentrations but fails to explain the 
apo(a) phenotype-specific elevation of plasma Lp(a). 
 
 In summary, the hallmarks of uremic dyslipidemia are 
hypertriglyceridemia; increased remnant lipoproteins (chylomicron 
remnants and IDL); reduced HDL cholesterol; and increased sdLDL, 
Lp(a), and apoA-IV. Elevated plasma LDL cholesterol level is not typical 
but can mostly be observed in patients with nephrotic syndrome and PD 
patients. 
 
Epidemiologic Association between Dyslipidemia and CV Outcome in 
CKD: 
 In the general population, high plasma concentrations of LDL 
cholesterol, low concentrations of HDL cholesterol, and to some extent 
high total triglyceride concentrations are associated with increased 
atherosclerotic CV risk3,4,74. In the dialysis populations, the 
preponderance of the literature, including cross-sectional75-77 and 
longitudinal studies78-85, does not support a strong association between 
dyslipidemia and CVD. This seemingly aberrant relationship may be due, 
in part, to the approaches of dyslipidemia assessment. The precise 
contributions of lipids to atherogenicity should probably be evaluated 
longitudinally using multiple measurements overtime, because the plasma 
lipid patterns change substantially as kidney disease progresses, as 
illustrated by the decline of plasma LDL levels from the nephrotic stage 
to the HD stage. Furthermore, the atherogenic potential of dyslipidemia in 
CKD may depend more on the apolipoprotein than on lipid abnormalities 
and may not always be recognized by measurement of plasma lipids 
alone, as suggested by Attman and Alaupovic75. An additional caveat is 
that, in many dialysis patients, CVD is caused or accentuated by other 
risk factors, such as volume overload, medial calcification, and 
arrhythmogenicity, and may not necessarily be related to atherosclerosis. 
 
Total Cholesterol: 
 In large administrative databases, the relationship between plasma 
total cholesterol and mortality in HD patient has been found to be U-
shaped87,88. The group with total cholesterol between 200 and 250mg/l 
had the lowest risk for death, whereas those with levels >350mg/dl had a 
relative risk of 1.3 fold and those with levels <10mg/dl had a relative risk 
of 4.2-fold. The association between low total cholesterol and increased 
mortality, however, was reduced after statistical adjustment for plasma 
albumin levels. Subgroup analysis provides further insights into the 
potential effects of plasma total cholesterol on clinical outcomes. A 
recent study of 1167 HD patients found that among those with low 
plasma albumin level (3.5 to 3.9g/dl), low plasma total cholesterol levels 
were also associated with increased all cause mortality. Among those 
with plasma albumin >4.5g/dl, however, high plasma total cholesterol 
levels were associated with increased mortality (10, as observed in the 
general population. This dichotomous relationship was confirmed in the 
Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study, 
which showed a nonsignificant negative association of cardiovascular 
mortality with plasma total as well as non-HDL cholesterol levels in the 
presence of inflammation and/or malnutrition; in contrast, there was a 
positive association between total and non-HDL cholesterol and mortality 
in the absence of inflammation or malnutrition. These observations are 
compatible with the hypothesis that the inverse association of total 
cholesterol levels with mortality in dialysis patients is mediated by the 
cholesterol lowering effect of malnutrition and/or systemic inflammation 
and not due to a protective effect of high cholesterol concentrations. 
 
IDL Cholesterol: 
 In observational studies, high plasma IDL cholesterol levels have 
been shown to be a risk factor independent of LDL cholesterol for 
coronary artery disease in the general population and may also be a 
predictor for aortic atherosclerosis in HD patients90. As discussed, IDL 
cholesterol is often elevated in uremia. Unfortunately, the current clinical 
assays do not differentiate between LDL cholesterol and IDL cholesterol. 
Therefore, current clinical assays may not accurately asses the 
atherosclerotic burden of plasma cholesterol in uremia. 
Lp(a) Concentrations and Apo(a) Polymorphism: 
 The association of Lp(a) with atherosclerotic complications has 
been investigated in numerous studies in dialysis patients. The results 
were inconsistent in prospective as well as in retrospective studies. This 
inconsistency might have been due, at least in pat, to the 
nonstrandardized assay method for Lp(a) in the past. When apo(a) 
phenotyping was performed in conjunction with plasma Lp(a) 
concentrations, however, an association between the apo(a) K-IV repeat 
polymorphism and CV complications was consistently observed. A cross 
sectional study in 607 HD patients showed an association between low 
molecular weight apo(a) phenotype with history of coronary events. Two 
large prospective studies also found a clear association of the apo(a) 
polymorphism with coronary events and total mortality, respectively. 
Kronenberg et al. followed 440 HD patients for 5 yr and found a strong 
association between the low molecular weight apo(a) phenotype and 
severe coronary events. In contrast, plasma Lp(a) in those with clinical 
events showed only a trend toward elevated levels and did not reach 
statistical significance. Similarly, the CHOICE Study recently reported 
small apo(a) isoforms to be associated with total mortality in an inception 
cohort of >800 incident dialysis patients who were followed for a median 
of 33.7 mo. In that study, Lp(a) concentrations were associated with CV 
events but not with total mortality. 
 
Apolipoproteins: 
 In the general population, plasma apoA-IV was reported to be 
lower in patients with CVD compared with control subjects, and this 
association was independent of HDL cholesterol and triglyceride 
concentrations. Similarly, participants in the Mild to Moderate Kidney 
Disease Study with CVD complications also had lower apoA-IV levels 
than those without. More data in various stages of CKD are required to 
confirm these findings. 
 
Hyperlipidaemia and Progression of Kidney Disease: 
 It has long been suggested that hyperlipidaemia could cause renal 
injury and contribute to the progression of renal disease7,110. There have 
been a number of observational studies showing that lipid abnormalities 
are associated with a reduction in kidney function in the general 
population. It is uncertain if it is the lipid abnormalities that cause the 
reduction in kidney function or if impaired renal function or proteinuria 
itself cause both the lipid abnormalities and reduction in renal 
function13,14. Most studies have been small and a meta-analysis of these 
studies to assess the effect of lipid reduction on the progression of renal 
disease has shown than lipid reduction may preserve GFR and reduce 
proteinuria. More recent studies have shown that HMG-CoA reductase 
inhibitors (statins) can reduce proteinuria and slow the decline in renal 
function. The effect of statins in reducing the decline in GFR was more 
significant in patients with proteinuria91-94. 
 
 Furthermore, it has been well established that proteinuria 
contributes to the progression of renal disease91,95. Despite optimal 
medical management with interventions to achieve tight blood pressure96 
and blood glucose control97, the use of angiotension converting enzyme 
(ACE) inhibitor98 and angiotension II99 receptor blocker (ARB) or 
combined therapy100, patients with renal failure are at risk for progressive 
deterioration of their renal function. Statins have been shown to reduce 
proteinuria and delay the rate of progression of renal disease in patients 
with proteinuria and hypercholesterolaemia92,93. These benefits are in 
addition to the effects of ACE inhibitor and ARB. However, recent data 
have suggested that statins have effects beyond lipid reduction and may 
have a beneficial anti-inflammatory effect in patients with normal or low 
cholesterol levels101,102. In addition to their lipid-lowering effects, statins 
can influence important pathways that are involved in the inflammatory 
and fibrogenic responses, which are commonly associated with many 
forms of progressive renal injury such as reduction in TGF-β production 
and inhibition of the proliferative actions of platelet-derived growth 
factor103,104.     
 
 Finally, statins can decrease coronary events in patients without 
cardiovascular disease105,106 and also reduce the mortality rates in patients 
with pre-existing coronary artery disease. Even for those with serum 
cholesterol levels as low as 3.5mmol/L and in diabetics without coronary 
artery disease or high cholesterol, statins have been demonstrated to be 
beneficial107,108. In patients with moderate CKD (GFR of 30 to 
59.99mL/min per 1.73m2) statins have been demonstrated to reduce the 
incidence of cardiovascular events109. 
 
Lipids in Nephrotic Syndrome: 
 Disturbed lipoprotein metabolism is a consistent feature of the 
nephrotic syndrome (NS). The development of this form of secondary 
dyslipidemia appears to be independent of the underlying renal disease 
and may substantially contribute to the increased cardiovascular risk that 
has been observed in these individuals as well as to the progression of 
renal failure. The most common lipid abnormalities in patients with NS 
are elevated concentrations of total and LDL-cholesterol as well as a 
predominance of cholesterol depleted small, dense LDL particles. 
However, in a considerable number of cases, elevated concentrations of 
triglycerides (due to accumulation of VLDL and remnant lipoproteins 
such as intermediate density lipoprotein (IDL)) can also be observed. In 
addition, individuals with nephrotic range proteinuria exhibit increased 
concentrations of Lp(a) that, in contrast to what is usually noticed in 
CKD patients without proteinuria, is not phenotype-specific. This means 
that most patients with the NS have Lp(a) concentrations that are 
substantially elevated compared with controls of the same apo(a) isoform. 
Finally, HDL-cholesterol levels have variously been reported to be 
increased, decreased, or normal in subjects with nephrosis. 
 
 The degree of hyperlipidaemia corrates directly with severity of the 
proteinuria and inversely with the serum albumin. As reduced GFR is by 
itself associated with hyperlipidaemia the strong and independent 
correlation between proteinuria and reduced GRF also increases the risk 
of hyperlipidaemia and proteinuria. Conversely, proteineria has an 
inverse correlation with the level of HDL, cholesterol. These risk factors 
likely predispose patients with nephrotic syndrome to an increased risck 
or coronary artery disease. 
 
 Among nephrotic patients, lipoprotein abnormalities were similar 
between diabetics and non-diabetic patients in a small study and both 
groups have elevated (TG), LDL and VLDL cholesterol and low HDL 
cholesterol. However, patients with diabetic CKD have lipoprotein 
abnormalities that are a reflection of renal insufficiency similar to that of 
patients with renal insufficiency due to other causes. These abnormalities 
however may be further accentuated by the diabetes and the abnormal 
metabolic control. 
 
Lipids in Hemodialysis and Peritoneal Dialysis: 
 Dialysis is very effective for the amelioration of uremic symptoms 
and certain features of uremic toxicity. The initiation of renal replacement 
therapy as well as the choice of dialysis modality may also influence the 
phenotypic characteristics of uremic dyslipidemia in patients with ESRD. 
however, the lipid and apolipoprotein profile that characterizes 
predialytic renal failure remains essentially unchanged during long-term 
hemodialysis (HD). Thus, HD patients usually display increased 
concentrations of intact or partially metabolized triglyceride rich 
lipoproteins, reduced serum levels of HDL cholesterol and elevated 
concentrations of Lp(a). Total and LDL cholesterol values are within 
normal limits or reduced in this patient population, whereas the 
subfractionation of apolipoprotein B-containing lipoproteins usually 
reveals a predominance of small, dense LDL particles. The 
pathophysiological mechanisms that underlie the alterations in lipoprotein 
metabolism in HD patients are generally similar with those described in 
predialysis renal failure individuals. However, the dialysis procedure may 
result in additional defects in lipid homeostasis (such as increased 
catabolic rate of apolipoprotein AI) that reinforce the clinical expression 
of these mechanisms. 
 
Dyslipidemia in kidney transplants: 
 Dyslipidemia, alone or as part of the metabolic syndrome, is an 
established risk factor for CVD mortality in kidney transplant recipients. 
The main causes are thought to be steroids, calcineurin inhibitors9-12, 
sirolimus, Diuretics and Betablockers. 
 
 About 60 % of kidney transplant recipients have total cholesterol 
level greater than 240 mg/dL (6.21 mmol/L); about 35 % have 
hypertriglyceridemia. Low level of high density lipoprotein cholesterol 
(<35 mg/dL [0.91 mmol/L]) occur in about 15 % kidney transplant15 
recipients- - a percentage similar to that in the general population. The 
concentrations of lipoprotein (a) and small, dense LDL-C, which are 
atherogenic, is increased.  
Lipid Management in CKD Patients Stages 3 to 4 (GFR 15 to 
50 ml/min/1.73 m2) 
The NKF and National Cholesterol Education Program Adult 
Treatment Panel (ATP) III offer similar guidelines for the management of 
dyslipidemia in patients with CKD; however, significant differences 
exist.In the NKF recommendations, CKD is regarded as a CHD risk 
equivalent and an annual lipid panel is recommended. As with any 
dyslipidemic patient, a comprehensive search for secondary causes of 
dyslipidemia should be conducted, including a search for endocrine 
disorders such as hypothyroidism and diabetes and medications such as 
corticosteroids, protease inhibitors, beta-blockers, diuretics, and estrogen. 
Elevated LDL-C 
Although patients with CKD frequently have multiple 
abnormalities in their lipid profile, LDL-C reduction is the primary goal 
of therapy. The NKF recommends LDL-C < 100 mg/dl for patients with 
CKD. Currently the NKF does not recommend a more aggressive LDL 
goal for patients with CKD and symptomatic atherosclerotic disease. 
Based on the amended ATP III guidelines, it might be prudent to treat to 
an LDL goal of < 70 mg/dl in patients with CKD with atherosclerotic 
disease. As in the general population, statins are the cornerstone of 
therapy for dyslipidemia. Treatment with a statin in conjunction with 
therapeutic lifestyle changes is usually required to obtain these goals. All 
statins can be used safely in patients with CKD; however, differences in 
the pharmacokinetic properties give some statins a safety advantage in 
patients with advanced CKD (GFR < 30 ml/min/1.73 m2). Because the 
excretion of atorvastatin in the kidneys is negligible, no dose adjustment 
for reduced GFR or hemodialysis is required. If combination therapy with 
a gemfibrozil is likely, then fluvastatin may be the safest choice. Other 
statins require dose adjustments as CKD becomes more advanced.  
In patients not at their LDL goal on atorvastatin or fluvastatin, 
ezetimibe or bile acid sequestrants can be added safely. Bile acid 
sequestrants' safety may be limited by their tendency to increase 
triglycerides, which frequently are elevated in CKD. In addition, bile acid 
sequestrants may be limited by their tendency to bind to other 
medications and reduce their absorption. 
Mixed Dyslipidemia 
Most patients with CKD have triglyceride as well as HDL 
abnormalities along with elevated LDL (mixed dyslipidemia). After LDL 
goal attainment, non-HDL should be the primary goal in the management 
of patients with CKD with mixed dyslipidemia. Non-HDL is the only 
lipid measurement that correlates positively with cardiovascular mortality 
in hemodialysis patients. Very-low-density lipoprotein and intermediate-
density lipoprotein are both known to be elevated in patients with CKD 
with mixed dyslipidemia, and therefore non-HDL may be a better marker 
of atherogenic cholesterol levels. Based on NKF recommendations, 
patients with CKD should be treated to an LDL-C < 100 mg/dl and a 
non–HDL-C < 130 mg/dl. 
Patients with mixed dyslipidemia frequently require combination 
therapy with a statin plus additional lipid-lowering drugs that could 
include ezetimibe, a fibrate, niacin, or omega-3 fatty acids. Although 
ezetimibe has a negligible effect on HDL and triglycerides, the addition 
of ezetimibe to a statin results in a significant additional reduction in 
non–HDL-C, which is the secondary therapeutic goal in mixed 
dyslipidemia . The combination of ezetimibe and a statin is relatively safe 
and well tolerated in patients with CKD  
The omega-3 fatty acids may also be used in combination with a 
statin. Although published data on this combination in patients with CKD 
is limited, omega-3 fatty acids do not have significant interactions with 
statins and do not require dose reductions for impaired renal function. 
Although fibrates can be used to treat mixed dyslipidemia, they 
need to be used carefully, because they are predominantly metabolized by 
the kidneys. According to the NKF guidelines, gemfibrozil is the fibrate 
of choice in patients with CKD. There is still controversy concerning the 
safety of fenofibrate in patients with CKD, because of its propensity for 
increasing serum creatinine and homocysteine to a greater degree than 
gemfibrozil. Due to the increased risk of rhabdomyolysis with fibrate and 
statin therapy in patients with CKD, the combination requires more 
vigilant monitoring, and patients need to report muscle symptoms 
immediately. Combined with a statin, fenofibrate clearly has advantages 
due to its lack of pharmacokinetic interactions with statins and lower 
propensity for rhabdomyolysis.] When gemfibrozil is selected for 
combination treatment with a statin, consideration should be given to 
changing the statin to fluvastatin, for which there is no pharmacokinetic 
interaction and fewer cases of rhabdomyolysis have been reported 
compared with other statins. Because of fluvastatin's lower efficacy in 
LDL reduction, the addition of a third drug, ezetimibe, may be necessary . 
Because CKD alone is a risk factor for rhabdomyolysis, the combination 
of a statin with any fibrate still needs to be weighed carefully from a risk-
benefit perspective.  
Niacin is also an option for the treatment of mixed dyslipidemia. 
Niacin has been shown to increase HDL-C, and reduce both lipoprotein 
(a) and triglycerides, which are elevated in patients with CKD, but its use 
is limited due to poor tolerability. The NKF clinical practice guidelines 
recommend reducing niacin dosing by 50% for GFR < 15 mg/ml/1.73 m2. 
Bile acid sequestrants are usually not an option in mixed hyperlipidemia, 
due to their tendency to increase triglycerides. 
Very High Triglycerides (> 500 mg/dl) 
The first goal for patients with fasting triglycerides > 500 mg/dl is 
to prevent pancreatitis. Fibrates are frequently started in this scenario, 
because they are better tolerated than niacin and are more efficacious 
triglyceride-lowering drugs than the statins. Currently, because of safety 
concerns, gemfibrozil would be recommended over fenofibrate . 
Although some studies suggest that the dose of gemfibrozil does not need 
to be reduced in severe renal failure, the NLA Safety Task Force on 
Lipid-Lowering Drugs recommends that the gemfibrozil dose should be 
reduced to 600 mg/day for patients with a GFR < 60 ml/min/1.73 m2 and 
avoided in patients with a GFR < 15 ml/min/1.73 m2. Finally, if 
fenofibrate must be used, the dose should not exceed 48 mg/day and 
creatinine levels should be monitored carefully.  
Another option for very high triglycerides is to treat with omega-3 
fatty acids derived from fish oil. The main active ingredients in fish oil 
are eicosapentaenoic acid (EPA) and docosahexaenoic (DHA). Four 
grams of omega-3 fatty acids per day, in the form of fish oil capsules, 
have been shown to reduce triglycerides 35% to 45%. The omega-3 fatty 
acids are safe in patients with CKD and have minimal drug interactions. 
Until recently, a major limitation was that over-the-counter preparations 
had only 200 to 300 mg omega-3 fatty acids per capsule, requiring the 
consumption of 12 to 16 capsules/day. The only available prescription-
brand omega-3 fatty acid contains almost 900 mg omega-3 fatty acids, 
requiring only 4 capsules/day. 
Lipid Management in Hemodialysis Patients (CKD Stage 5; GFR 
< 15 ml/min/1.73 m2) 
The options for hemodialysis CKD stage 5 patients are more 
limited than patients with CKD stages 1 through 4. For patients with 
elevated LDL-C, choosing statins with limited renal excretion, such as 
atorvastatin or fluvastatin, may be more important . In mixed 
dyslipidemia, omega-3 fatty acids may have a more prominent role, 
because the NLA recommends avoiding fibrate use in patients with a 
GFR < 15 ml/min/1.73 m2. In patients with very high triglycerides, 
clinicians can treat with 3 to 4 g/day omega-3 fatty acids, or if a fibrate 
must be used then gemfibrozil can be given at a reduced dose of 
600 mg/day. 
Proposed Treatment Algorithm for Lipid Management in Patients 
With CKD (Stage 3 to 5) 
 
Lipid Disorder Therapeutic Option  
Moderate to severe CKD, stages 3 to 4 (GFR 15–59 ml/min/1.73 m2) 
 Elevated LDL-C 1. Atorvastatin, add ezetimibe if not at LDL-C goal 
2. Fluvastatin, add ezetimibe if not at LDL-C goal 
   Mixed 
dyslipidemia* 
(not at non-HDL† 
goal) 
1. Atorvastatin or fluvastatin + ezetimibe  
2. Fluvastatin + gemfibrozil 600 mg/day + 
ezetimibe if not at non-HDL goal  
3. Statin + omega-3 fatty acids, add ezetimibe if not 
at non-HDL goal  
4. Statin + fenofibrate 48 mg/day, add ezetimibe if 
not at non-HDL goal 
   Very high 
triglycerides 
(triglyceride 
≥500 mg/dl) 
1. Gemfibrozil 600 mg/day  
2. Omega-3 fatty acids 3–4 g/day  
3. Fenofibrate 48 mg/day 
CKD stage 5 (hemodialysis or GFR <15 ml/min/1.73 m2) 
   Elevated LDL-
C 
Atorvastatin (10–80 mg/day) or fluvastatin 40 mg/day, 
add ezetimibe if not at LDL-C goal 
   Mixed 
dyslipidemia 
Atorvastatin or fluvastatin 40 mg/day, add ezetimibe 
10 mg/day or omega-3 fatty acids 3–4 g/day if not at 
non-HDL goal 
   Very high 
triglycerides 
Omega-3 fatty acids 3–4 g/day or gemfibrozil 
600 mg/day 
 
                               
 
 
 
AIMS AND OBJECTIVES 
 
 
 
¾ To study the Lipid abnormalities in patients with Chronic renal 
failure.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                MATERIALS AND METHODS     
 
Setting:- 
 Chronic renal failure patients admitted in medical wards of Govt. 
Rajaji Hospital, Madurai. 
 
Collaborating departments  
    1.  Department of Nephrology 
          Madurai Medical College, Madurai. 
   
    2.Department of Bio Chemistry  
      MMC, Madurai. 
 
Design of the Study : Cross sectional Study 
 
Period of Study  : From February 2008 to July 2008  
  
Sample Size   : 25- controls  
      56-Chronic renal Failure Patients(study cases) 
 
 Definitions: 
Chronic Kidney disease: 
  It is defined by the presence of kidney damage or decrease in 
kidney function (Glomerular filtration ratio < 60 ml/mt/1.73m2) for the 
three months or more, irrespective of the etiology.  
 
Kidney damage: 
 It is defined as structural or functional abnormalities of kidney, 
initially without decreased GFR. Kidney damage can be diagnosed by 
any abnormalities in the blood (elevated blood urea and creatinine) urine 
(proteinuria, granular casts), imaging study or by biopsy. 
 
Kidney Failure: 
 It is defined as either level of GFR decreased to <15ml/min, which 
is accompanied in most cases by signs and symptoms of uremia or a need 
for initiation of kidney replacement therapy (dialysis or transplantation) 
for treatment for complications of decreased GFR, which would 
otherwise increase the risk of mortality and morbidity. 
 
 End stage renal failure (ESRD) is defined as a level of GFR to 
<5ml/min where survival is not possible without renal replacement 
therapy. 
    GFR is the best estimate of kidney function. The serum creatinine 
alone is not at accurate measure of the glomerular filtration rate. 
Creatinine is secreted by the renal tubules and as the renal function 
worsens the amount secreted increases. 
 
 GFR can be estimated using the cockcroft – Gault formula2   
140-age x weight (kg) CrCL (ml/mt) = 72 x S.creatine (mg/dl) x 0.85 (for women) 
 
Dyslipidemia: 
 Any abnormality in plasma lipoprotein concentration or 
composition that is associated with an increased risk for atherosclerotic 
cardiovascular disease.  
 
Lipid profile: 
 Plasma level of total cholesterol, low density lipoprotein 
cholesterol, high density lipoprotein cholesterol and triglycerides.  
 
Inclusion criteria: 
1. Clinical  
Anaemia of chronic renal failure  
Hypertension     
Uremic symptoms – Three months duration        
2. Biochemical 
a. Elevated blood urea & serum creatinine  
3. Ultra sonographic 
a. Contracted kidney 
b. Increased cortical echogenicity  
c. Loss of cortico medullary differentiation 
 
Exclusion criteria:  
 Patients with chronic renal failure with the following conditions 
were excluded from this study. 
1. Diabetes mellitus 
2. Nephrotic syndrome 
3. Obesity BMI >30 
4. Liver disease 
5. Alcohol abuse / smokers 
6. Thyroid dysfunction 
7. Taking steroids, diuretics (Thiazides), beta blockers. 
8. Oral contraceptive pills 
9. Lipid lowering drugs. 
 
 
These patients were evaluated on the basis of the proforma on the 
following guidelines 
¾ Clinical history and physical examination 
¾ Routine investigations like blood HB%, total count, 
differential count, blood sugar, urine analysis. 
¾ Renal parameters inducting blood urea, serum creatinine. 
¾ Fasting lipid profile 
¾ ultrasonogram abdomen .      
 
All specimens were analyzed within 4 to 6 hours of collection. 
Total cholesterol and triglycerides in the plasma were measured 
enzymatically and then the cholesterol in the supernatant is measured 
after precipitation of APO-B containing lipoprotein to determine the HDL 
cholesterol. LDL cholesterol is estimated by using the friedewald formula.    
 
 FRIEDEWALD FORMULA appears to be the most practical & 
reliable method for determining LDL-cholesterol in clinical practice. 
 
 LDL-Cholesterol=Total cholesterol-[HDL-C+(Triglycerides/5)] 
 VLDL is estimated by dividing the plasma triglycerides by 5 
reflecting the ratio of cholesterol to triglyceride in VLDL particles. This 
formula is reasonably accurate if test resolution is obtained on fasting 
plasma and if the triglyceride level is less than 350mg/dl. The accurate 
determination of LDL-C level in conditions with triglyceride levels 
greater than this requires application of ultra centrifugation techniques 
(BETA  QUANTIFICATION) 
 
Ethical Committee approval : Obtained 
Consent    : Informed consent was obtained 
Financial support    : Nil 
Conflict of interest   : Nil 
 
Statistical Tools  
The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of 
computer using Epidemiological Information Package (EPI 2002).  
 Using this software,  range, frequencies, percentages, means, 
standard deviations, chi square and  'p'  values were calculated. Kruskul 
Wallis chi-square  test was used to test the significance of difference 
between quantitative variables. A 'p' value less than 0.05 is taken to 
denote significant relationship. 
RESULTS 
 
         
Table 1 : Age distribution 
Cases Controls Age group 
No. % No. % 
41-45 years 1 1.8 4 16 
46-50 29 51.8 12 48 
51-55 19 33.9 5 20 
55-59 7 12.5 4 16 
Total 56 100 25 100 
Range 
Mean 
S.D. 
45-57 
51.2 
3.0 
41-59 
50.4 
4.9 
‘p’ 0.1536 
Not significant 
 
 
The mean age of the patients were 51.2 years and maen age of the 
controls were 50.4 years.There was no significant difference between the 
study cases and controls in the age(p value 0.153).Hence they are 
comparable. 
Table 2 : Sex distribution 
 
 
Cases Controls  Sex 
No. % No. % 
Male 28 50 10 40 
Female 28 50 15 60 
‘p’ 0.7945 
Not significant 
 
 
 
There was no significant difference between study group and 
controls regarding the sex distribution ( p value0.7945).Hence they are 
comparable.                 
Table  3 :  BMI 
 
 
 
BMI Cases 
 
Control cases 
Range 
Mean 
S.D. 
22-26 
24.55 
1.08 
22-26 
24.76 
1.09 
‘p’ 0.3668 
Not significant 
 
 
 
The mean BMI of study cases was 24.55 Kg/m2 and that of controls 
was 24.76 Kg/m2 .There was no significant difference between the study 
group and controls in this parameter.Hence they are comparable. 
 
Table 4 : Lipid Profile 
 
 
 
 
Cases 
 
Controls 
 
Lipid 
Range Mean S.D. Range Mean S.D. 
 
‘p’ 
TC 158-269 213.6 14.9 132-245 207.8 22.1 0.1761 
Not 
Significant 
TGL 110-264 205.9 44.9 112-180 148.0 16.3 0.0001 
Significant 
HDL 16-75 39 18.5 38-86 60.7 14.3 0.0001 
Significant 
LDL 110-171 139.4 16.4 110-172 127.2 15.6 0.1031 
Not 
Significant 
 
  
 
 
 
 
 
TOTAL CHOLESTEROL 
The mean total cholesterol in the study population was 213.6 mg/dl 
and in the control group it was 207.8 mg/dl. There is no statistically 
significant difference between the serum cholesterol levels of cases and 
controls.( p value 0.1761).   
 
TRIGLYC ERIDES 
The mean triglyceride in study group was 205.9 mg/dl and 148 
mg/dl in control group. There is significant difference between the two 
groups as suggested by the p value 0.0001. 
 
HDL CHOLESTEROL 
HDL in our study showed a significant reduction in CRF cases 
compared with controls. The mean HDL in cases were 39 mg/dl and 60.7 
mg/dl in controls. The difference was statistically significant with a p 
value of 0.0001. 
 
LDL CHOLESTEROL 
LDL Cholesterol was high in cases compared to controls, but the 
difference was not significant statistically. The mean LDL in cases was 
139.4 mg/dl and 127.2 mg/dl in controls. The p value was 0.1031( Not 
significant).              
DISCUSSION 
 
 
Chronic kidney disease results when a disease process affects the 
structural or functional integrity of the kidneys. Chronic kidney failure is 
the result of chronic kidney disease. Cardiovascular disease is a major 
cause of mortality in patients with mild to moderate chronic kidney 
disease and end stage renal disease. Dyslipidemia has been established as 
a well known traditional risk factor for cardiovascular disease in general 
population and it is well known that patient with CKD exhibit significant 
alterations in lipoprotein metabolism, which in their most advanced form 
may result in the development of severe dyslipdemia. 
 
              This study was done to identify the lipid abnormalities that occur 
in CRF patients admitted in Govt. Rajaji Hospital, Madurai. 
 
  
             A total of 56 cases who fulfilled the diagnostic criteria for CRF 
were included in the study. 25 age, sex and BMI matched healthy controls 
who fulfilled the inclusion and exclusion criteria were taken for 
comparing the lipid profile. 
 
            Among 56 cases the mean age was 51.2 yrs with the range of 45 – 
57 yrs The mean age of controls was 50.4 yrs and range was 41 – 59 yrs. 
There was no significant difference between cases and controls with 
regard to the age. ( P value – 0.1536 ). So they can be compared. 
 
            There were equal number of males and females in the study group,  
28 males and 28 females. Among the 25 controls, 10 were males and 15 
were females. There was no significant difference between cases and 
controls as far as sex is concerned. ( P value – 0.7945 ) 
 
             The mean BMI of the cases was 24.55 kg / m2 .The mean  BMI 
of the controls was 24.76 kg / m2. There was no significant difference 
between cases and controls with respect to BMI. 
 
             On analyzing the lipid profile and comparing the CRF cases with 
controls we found that there is significant increase in triglycerides and 
significant decrease in HDL–cholesterol. The change in total cholesterol 
and LDL-C between cases and controls was not significant. 
 
                                      
TOTAL CHOLESTEROL: 
 
               The mean total cholesterol in the CRF cases was 213.6 mg/dl 
and that of the controls was 207.8 mg/dl. There was no statistically 
significant difference in this parameter. (P value – 0.1761).This 
observation was similar to the results obtained by E.Kimak and 
coworkers in their work on plasma lipoproteins in CRF patients. They 
also concluded that total cholesterol is not increased significantly in 
patients with CRF114. 
 
TRIGLYCERIDES: 
 
Significant increase in serum triglycerides was seen in cases 
when compared with controls. Mean triglycerides was 205.9 mg in cases 
and 148 mg / dl in controls.( P  value is 0.0001). This result was in 
concordance with the work done by E.Kimak and team, in which they 
demonstrated significant increase in Triglycerides, LDL and Apo-B  
concentrations114.In another study, done by Bhagwat.R , Joshi S P and 
team, they concluded that CRF patients were having  marked 
triglyceridemia of  232 mg / dl as compared to controls.(P value less than 
0.01) 111.Another Indian study on dyslipidemia in patients with CRF and 
renal  transplantation by B.Shah, S.Nair and coworkers they demonstrated 
that triglycerides was elevated significantly in CRF patients on 
conservative management117.These results shows that 
hypertriglyceridemia is an important lipid abnormality in patients with 
CRF. 
 
LDL CHOLESTEROL: 
 
                  Our study demonstrated an increase in LDL cholesterol 
between cases and controls. (139.4 mg/dl vs 127.2 mg / dl ). This was not 
significant statistically.p value(0.1031). This was similar to the study by 
Bhagwat R and Joshi S P where they found that LDL cholesterol in CRF 
patients showed an increase compared to controls which is not 
statistically significant111. Study by E.Kimak and team  showed results 
not comparable to our study. LDL cholesterol showed significant increase 
among CRF patients compared with controls in their study114. Although 
the total concentrations of  LDL are not significantly increased there is 
predominance of small dense particles which are particularly susceptible 
to oxidation in CRF. These small particles are thought to be more 
atherogenic than larger LDL substrates112.  
 
HDL CHOLESTEROL : 
 
                Our study demonstrated a significant decrease in HDL in CRF 
cases when compared with controls (  39mg/dl   vs  60.7mg/dl   ( Pvalue 
0.001  ).  This was in concordance with the results obtained by Bhagwat 
R and team where they found HDL cholesterol to be significantly low. 
(20 +/- 11)mg/ dl( P value less than 0.001) in CRF groups111. Patients 
with CKD generally have reduced plasma HDL cholesterol 
concentrations when compared with non uraemic individuals. 
 
 
 
 
 
 
 
 
 
CONCLUSIONS 
 
 
1. Lipid abnormalities is common in CRF. 
2. Total cholesterol changes are not statistically significant. 
 
3. Triglycerides shows statistically significant increase in CRF 
cases when compared with normal. 
4. LDL – C is increased in CRF patients but it is not statistically 
significant when compared with controls. 
5. HDL – C shows a statistically significant decrease in CRF 
patients compared with controls. 
 
   
 
 
            
 SUMMARY 
 
          
  Dyslipidemia is a fairly common occurrence in CRF patients. 
Cardiovascular mortality in patients with CRF is related to dyslipidemia. 
This study was done to identify the lipid abnormalities and its 
significance in CRF  patients by comparing with age, sex and BMI of 
matched healthy control population. 
 
After institutional ethical clearance with an informed consent and  
with inclusion and exclusion criteria, 56 cases of CRF were taken as 
study cases and Three fasting lipid profile were estimated. 25 age, sex 
and BMI matched healthy Population were taken as controls. The data 
were entered in master sheet and analyzed statistically. 
 
Dyslipidemia is seen in CRF patients. The total cholesterol, even 
though it was high in CRF cases compared with controls, but the change 
was not significant statistically. Triglycerides showed a statistically 
significant increase in CRF cases. LDL-C was elevated in CRF cases but 
the change was not significant statistically. HDL-C on the other hand 
showed a statistically significant drop compared to controls. These lipid 
abnormalities may be an important contributing factor to the 
cardiovascular mortality in patients with CRF. 
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PROFORMA 
 
 Name                                    Age                                                 Sex              
 
IP Number                            Occupation                                     Address 
 
Presenting complaints 
 
Oliguria 
 
Pedal edema 
 
Nausea,vomiting 
 
Pruritus 
 
Hiccups 
 
Facial puffiness 
 
Dyspnea 
 
Past history 
 
Diabetes 
 
Hypertension 
 
TIA 
 
Stroke 
 
Drug history 
 
Thiazides,Beta blockers,Steroids 
 
Family history 
 
H/o Diabetes,Hypertension,Hyperlipidemia 
 
 
Personal history 
 
Smoking,Alcoholism 
 
General examination 
 
Pallor             Icterus        Cyanosis          Clubbing          LNE 
  
Pedal edema                     Facial puffiness                        JVP 
 
Evidence for hyperlipidemia 
 
Xanthelasma    Arcus       Tendinous or Eruptive xanthoma 
 
Vitals      
 
Pulse              BP           RR               Temp           Fundus 
 
CVS 
 
RS 
 
Abdomen 
 
CNS 
 
Investigations  
 
Urine 
 
           Albumin,Sugar,Deposits 
 
          24 hour urine protein 
 
Blood 
 
          Sugar 
 
         Hb,TC,DC 
 
Renal function tests 
 
                      Blood Urea 
 
                      Serum creatinine 
 
USG abdomen for kidney size 
 
Fasting lipid profile 
 
                    Total cholesterol,HDL,LDL,Triglycerides 
 
FINAL DIAGNOSIS 
 
             
 
 
 
 
 
 
 
 
 
 
APPENDIX IV 
 
ABBREVIATIONS 
 
ACE   –  Angiotensin converting enzyme 
ATP   –  Adult treatment panel 
ARB   –  Angiotensin receptor blocker 
BMI   –  Body mass index 
CETP  –  Cholesteryl ester transfer protein 
CKD   –  Chronic kidney disease 
CRF   –  Chronic renal failure 
ESRD –  End stage renal disease 
GFR   –  Glomerular filtration rate  
HD   –  Hemodialysis 
HDL   –  High density lipoprotein 
HL    –  Hepatic lipase 
IDL   –  Intermediate density lipoprotein 
LDL   –  Low density lipoprotein 
LCAT –  Lecithin cholesterol acyl tranferase 
LPL   –  Lipoprotein lipase 
MTR   –  Microsomal transfer protein 
NS   –  Nephrotic syndrome 
PD   –  Peritoneal dialysis 
RRT   –  Renal replacement therapy 
TC   –  Total cholesterol 
TGL   –  Triglycerides 
VLDL –  Very low density lipoprotein  
 
 
APPENDIX II 
 
MASTER CHART CASES 
 
 
 
sl no sex age 
    
BMI sugar urea creatinine
Creatinine 
clearance TC TGL HDL LDL
1 M 50 25 98 102 2.2 34 246 223 26 146 
2 F 48 25 102 108 2.2 35 234 212 28 154 
3 F 51 26 113 90 28 36 221 239 25 148 
4 F 53 26 90 102 2.9 37 224 215 30 151 
5 M 50 26 94 94 2.6 34 211 219 32 145 
6 M 54 25 115 88 2.3 35 219 206 23 155 
7 F 49 26 102 92 2.3 37 229 218 26 159 
8 F 50 23 95 75 2.9 36 227 233 30 150 
9 F 56 24 110 106 2.7 38 247 218 61 142 
10 M 50 25 97 94 2.5 34 234 245 27 158 
11 F 57 24 114 70 2.8 35 230 240 25 157 
12 M 48 24 106 80 2.2 40 196 110 60 114 
13 M 54 25 84 74 2.5 41 217 147 71 117 
14 M 47 26 90 85 2.1 39 221 144 62 130 
15 F 56 23 105 76 2.9 38 240 138 65 148 
16 F 50 25 108 79 2 40 225 150 70 125 
17 M 47 25 110 81 2.8 41 214 127 71 118 
18 F 56 25 116 78 2 38 220 136 64 129 
19 F 50 25 98 90 2.7 40 211 155 70 110 
20 M 52 26 100 78 2.7 39 223 140 75 120 
21 M 48 25 106 75 2.2 37 255 241 64 143 
22 M 50 23 111 72 2.9 41 227 151 72 125 
23 F 49 25 98 80 2.8 40 239 147 60 130 
24 F 54 24 107 83 2.6 38 220 154 61 134 
25 F 54 25 107 83 2.8 36 225 149 60 150 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26 F 50 23 90 89 2.6 39 209 140 67 114 
27 M 54 24 118 128 5.6 14 237 258 20 164 
28 M 48 22 115 124 4.2 15 237 244 22 154 
29 F 50 25 88 126 4.4 16 224 237 24 154 
30 M 53 24 94 114 4.1 17 225 235 26 145 
31 F 57 26 108 118 5.2 14 233 236 25 161 
32 M 49 25 111 123 5.7 15 230 226 27 157 
33 F 50 25 120 135 4.5 16 221 223 28 148 
34 M 57 25 97 127 4.2 14 227 243 19 160 
35 F 51 24 114 119 3.9 15 232 237 29 156 
36 F 49 25 80 103 3.9 16 222 244 25 148 
37 M 51 24 94 106 3.9 17 217 227 27 145 
38 F 50 25 110 123 5.2 14 231 223 24 163 
39 F 56 26 108 119 4 15 241 234 23 171 
40 M 49 26 102 115 5 15 235 258 22 161 
41 M 50 25 120 122 4.8 16 232 237 26 150 
42 M 48 24 106 124 6.9 8 216 248 38 129 
43 M 54 24 110 130 9.4 6 199 246 30 120 
44 F 50 25 94 118 6.8 9 158 148 38 118 
45 F 46 23 112 134 12.6 6 218 264 34 131 
46 M 51 22 118 164 12.6 5 183 260 16 115 
47 M 55 24 88 130 10.6 5 201 254 24 126 
48 F 52 22 99 144 7.5 8 187 152 41 116 
49 M 54 24 108 160 11.8 6 195 240 20 127 
50 M 50 23 118 132 16 5 212 238 30 135 
51 M 52 24 84 115 10.5 7 209 230 31 132 
52 M 45 25 104 158 13.6 6 219 236 30 140 
53 F 50 24 116 148 13.8 5 218 246 32 137 
54 F 46 26 84 126 7.7 9 179 156 28 120 
55 F 54 25 96 134 8.5 8 228 196 34 135 
56 M 53 24 102 128 6.6 9 209 156 64 114 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTER CHART CONTROLS 
 
 
sl 
no sex age 
    
BMI sugar urea creatinine
Creatinine 
clearance TC TGL HDL LDL 
1 M 59 25 105 21 0.8 105 220 125 60 147 
2 F 48 26 98 28 0.6 106 208 136 74 118 
3 F 59 26 87 19 0.7 111 226 158 70 125 
4 M 53 25 80 22 0.6 109 221 144 85 157 
5 M 48 23 76 26 0.8 107 132 128 65 112 
6 F 46 22 78 21 0.7 109 183 134 55 128 
7 F 55 25 98 24 0.8 111 208 150 72 114 
8 M 49 23 116 25 0.9 112 222 170 86 122 
9 M 56 25 94 29 0.8 110 209 145 76 124 
10 F 46 26 112 32 0.8 107 197 154 72 115 
11 F 51 24 108 28 0.7 113 209 140 64 127 
12 F 41 24 105 32 0.7 114 212 158 70 126 
13 F 48 24 88 25 0.8 112 200 180 64 110 
14 F 46 24 96 26 0.8 107 203 142 80 115 
15 F 52 25 94 64 1.2 109 232 154 40 156 
16 F 47 25 108 68 0.9 110 238 150 44 114 
17 M 50 26 102 70 1 112 232 155 47 154 
18 M 48 26 88 78 1.1 113 200 143 40 110 
19 F 44 24 90 72 1.3 113 245 176 38 172 
20 M 47 25 76 56 1.2 114 197 112 47 128 
21 F 43 24 84 64 0.9 115 205 144 51 126 
22 F 51 25 110 58 1.3 105 202 168 49 120 
23 F 50 25 102 60 0.7 105 183 154 53 130 
24 M 50 26 94 60 1 111 209 124 61 124 
25 M 45 26 88 48 1 110 203 155 54 118 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KEY TO MASTER CHART 
 
 
BMI  -   Body mass index             (Kg/m2)    
 
TC  -    Total cholesterol               (mg/dl)  
 
HDL -  High density cholesterol  (mg/dl)   
 
LDL -   Low density cholesterol    (mg/dl) 
 
TGL -  Triglycerides                      (mg/dl) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 AGE DISTRIBUTION 
Fig 1 
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SEX DISTRIBUTION 
 
Fig 2 
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LIPID PROFILE 
 
Fig 3 
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